Meng-Fen Ho

Title: Innovator Meng-Fen Ho: Contributions to SGLT2 Inhibitors and Docetaxel

Introduction

Meng-Fen Ho, an inventive mind based in Anding, Taiwan, has made significant strides in the pharmaceutical field with his innovative research and patented inventions. With a total of four patents to his name, he has contributed valuable materials that enhance the effectiveness of treatments in medical applications.

Latest Patents

Meng-Fen Ho's recent patents include groundbreaking work on crystalline and non-crystalline forms of SGLT2 inhibitors. His invention provides amorphous forms and crystalline complexes of these inhibitors, particularly in pharmaceutically acceptable forms. The crystalline forms of the SGLT2 inhibitor canagliflozin are uniquely designated as Forms CS1, CS2, CS3, CS4, and CS5. Additionally, he has developed a new anhydrous crystalline form of docetaxel, along with a process for the preparation of both anhydrous docetaxel and docetaxel trihydrate. These advancements underscore his dedication to improving pharmaceutical materials.

Career Highlights

Meng-Fen Ho has had the opportunity to work with notable companies such as Scinopharm Taiwan Ltd. and Scinopharm Singapore Pte Ltd. His time at these institutions has been marked by innovative research that pushes the boundaries of drug development and formulation.

Collaborations

Throughout his career, Meng-Fen has collaborated with esteemed professionals in the field, including his coworkers Shu-Ping Chen and Tsung-Yu Hsiao. These partnerships have played a vital role in driving forward the innovative ideas and patent applications that Meng-Fen has developed.

Conclusion

Meng-Fen Ho exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents not only enhance existing therapies but also pave the way for future advancements. As he continues to explore novel materials and methods, his work remains invaluable in the quest for effective medical solutions.